Date: 2014-02-11
Type of information: Development agreement
Compound: companion diagnostics
Company: Ventana Medical Systems, a member of the Roche Group (USA - Switzerland) Bayer (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
Disease:
Details: * On March 11, 2014, Ventana Medical Systems, a member of the Roche Group, has announced that it has entered into a multi-year agreement with Bayer Pharma to develop companion diagnostics, with a focus on immunohistochemistry (IHC), across Bayer?s portfolio of targeted therapy projects. This new agreement extends an already existing collaboration and focuses on the development of diagnostic tests for Bayer?s biomarker targeted therapeutics from early discovery through commercialization. Under the terms of the new agreement, Ventana will create an expert team with resources exclusively assigned to Bayer projects and will work on the development of companion diagnostic tests for targeted therapies in the Bayer development portfolio.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
